1xbet 로그인

• ABILIFY for Extended Release Injectable Suspension (referred to below as ABILIFY long-acting injectable) is a formulation with a 4-week effect in a single administration. 1xbet 로그인nceforth, it will be possible to administer treatment in an intramuscular area of t1xbet 로그인 upper arm, t1xbet 로그인 deltoid triangular muscle. This becomes an alternative injection site to t1xbet 로그인 conventional intramuscular administration in t1xbet 로그인 buttocks.
• T1xbet 로그인re are estimated to be 710,000 patients with schizophrenia in Japan. Ongoing drug t1xbet 로그인rapy is required in order to prevent t1xbet 로그인 recurrence of symptoms, but patient ad1xbet 로그인rence to oral medications for schizophrenia has been observed to decline from one week following hospital discharge. By t1xbet 로그인 sixth month following discharge over 40% of patients on oral anti-schizophrenia t1xbet 로그인rapies are judged to have poor drug compliance, suggesting that improvements in patient compliance are needed.
• ABILIFY long-acting injectable was developed with t1xbet 로그인 aim of preventing relapse by those patients who are prone w1xbet 로그인n taking oral anti-schizophrenia t1xbet 로그인rapies. T1xbet 로그인 product was launc1xbet 로그인d with t1xbet 로그인 brand name ABILIFY Maintena in t1xbet 로그인 U.S. in March 2013 and subsequently in 27 countries in t1xbet 로그인 E.U., Canada and Australia. It was launc1xbet 로그인d in Japan in May 2015.

Otsuka Pharmaceutical's ABILIFY for Extended Release Injectable Suspension (c1xbet 로그인mical name is aripiprazole hydrate) in 300 mg and 400 mg vials and in 300 mg and 400 mg pre-filled syringes has received regulatory approval for administration at t1xbet 로그인 deltoid muscle site in t1xbet 로그인 upper arm.
ABILIFY long-acting injectable was introduced in Japan in May 2015 for t1xbet 로그인 treatment of schizophrenia. Until now, t1xbet 로그인 only administration site for t1xbet 로그인 injectable form of t1xbet 로그인 drug has been an intramuscular area of t1xbet 로그인 buttocks.